TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells

Arsenic trioxide (ATO) has been shown to be effective in treating acute promyelocytic leukemia. TP53 mutated/null tumor cells are more sensitive to ATO treatment compared to tumor cells carrying wildtype TP53 gene copies. However, it is unclear whether TP53 inhibitors can increase the sensitivity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haiwei, Wang, Xinrui, Xu, Liangpu, Zhang, Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886521/
https://www.ncbi.nlm.nih.gov/pubmed/35030298
http://dx.doi.org/10.1002/2211-5463.13366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886521/
https://www.ncbi.nlm.nih.gov/pubmed/35030298
http://dx.doi.org/10.1002/2211-5463.13366

Ejemplares similares